At a Glance
HR+, HER2- adjuvant breast cancer
IBRANCE® (palbociclib) is indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women, fulvestrant in women with disease progression following endocrine therapy.
Applications In Development:
Initial therapy in combination with letrozole for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) metastatic breast cancer.
In January 2016, Royalty Pharma commits to fund a Pfizer program testing Ibrance in adjuvant breast cancer